What does the research say about CTACK and GDF-15?

CTACK and GDF-15

There is 1 paper on CTACK and GDF-15 in aging research: 1 trial in people.

1 paper studies it1 finding

1 new paper in 30 daysSee all 1

“Exploratory biomarker analyses identified nominal between-group differences in CTACK (p = 0.015) and GDF-15 (p = 0.022), without adjustment for multiple testing”

Unlocking the Healthy Aging Potential of Novel NMN-Based Nutritional Formulations: Cardiopulmonary, Cognitive, and Aging-Related Outcomes in a 42-Day Open-Label StudyNutrients2026doi:10.3390/nu18213490

Human trial1

Associations

Expanded NMN-based nutritional formulation

mixedin humans1

1 study

Expanded NMN-based nutritional formulation is associated with CTACK and GDF-15 in humans (Exploratory placebo-versus-expanded-formulation subset; no adjustment for multiple testing) (CTACK p = 0.015; GDF-15 p = 0.022; directions not reported).
“Exploratory biomarker analyses identified nominal between-group differences in CTACK (p = 0.015) and GDF-15 (p = 0.022), without adjustment for multiple testing”
Human trialExploratory placebo-versus-expanded-formulation subset; no adjustment for multiple testingeight-component formulation42 days
Unlocking the Healthy Aging Potential of Novel NMN-Based Nutritional Formulations: Cardiopulmonary, Cognitive, and Aging-Related Outcomes in a 42-Day Open-Label Study
NutrientsOct 23, 2026

More on Expanded NMN-based nutritional formulation

Latest

1 paper in 12 months

NutrientsOct 29

Unlocking the Healthy Aging Potential of Novel NMN-Based Nutritional Formulations: Cardiopulmonary, Cognitive, and Aging-Related Outcomes in a 42-Day Open-Label Study

Non-randomized trial in 40 peopleNicotinamide mononucleotide

Paper